Patrick Dillon
University of Virginia · University of Virginia Health System
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Patrick Dillon as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 16:40 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT04796220 · Focused Ultrasound and Gemcitabine in Breast CancerPatrick Dillon, MD · active not recruiting · Breast Cancer, Breast Neoplasms · principal investigator
- Ph2NCT04038489 · COX Inhibition and Biomarkers During Neoadjuvant Chemoendocrine Therapy for ER+, HER2- Stage I-III Breast CancerUniversity of Virginia · withdrawn · Breast Cancer, Estrogen Receptor-positive Breast Cancer · principal investigator
- Ph1NCT03473639 · A Pilot Study of the Combination of Entinostat With Capecitabine in High Risk Breast Cancer After Neo-adjuvant TherapyUniversity of Virginia · completed · Metastatic Breast Cancer, Breast Cancer · principal investigator
- Early Ph1NCT03473691 · Pilot Study of Glembatumumab Vedotin Following Doxorubicin and Cytoxan as Neo-adjuvant Therapy in Gp-NMB-expressing High Risk Triple Negative Breast CancerUniversity of Virginia · withdrawn · Triple Negative Breast Cancer · principal investigator
- Ph1/Ph2NCT03272334 · Her2-BATS and Pembrolizumab in Metastatic Breast CancerUniversity of Virginia · active not recruiting · Metastatic Breast Cancer · principal investigator
- Ph1NCT03237572 · Focused Ultrasound and Pembrolizumab in Metastatic Breast CancerPatrick Dillon, MD · terminated · Breast Cancer · principal investigator
- Ph2NCT01524692 · Study of Dovitinib (TKI258) in Adenoid Cystic CarcinomaUniversity of Virginia · completed · Adenoid Cystic Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 16:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 16:40 UTC. The ranking covers the 200 most relevant of 31 PubMed records, and a shared surname and initials can bring in a namesake. All 31 on PubMed
- Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.Gastroenterology · 2013777 citationsRCR 23.8
- 670 citationsRCR 45.8
- Extracorporeal circulation in neonatal respiratory failure: a prospective randomized study.Pediatrics · 1985514 citationsRCR 22.7
- Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma.Clin Cancer Res · 2022116 citationsRCR 7.7
- 115 citationsRCR 3.4
- 107 citationsRCR 3.1
- A comparison of superficial versus combined (superficial and deep) cervical plexus block for carotid endarterectomy: a prospective, randomized study.Anesth Analg · 200072 citationsRCR 2.7
- Prophylactic urokinase in the management of long-term venous access devices in children: a Children's Oncology Group study.J Clin Oncol · 200469 citationsRCR 2.4
- A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma.Clin Cancer Res · 201768 citationsRCR 3.0
- A computerized harm minimization prevention program for alcohol misuse and related harms: randomized controlled trial.Addiction · 200965 citationsRCR 2.8